Insight, China's Pharmaceutical Industry

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...

Company Drug

CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination

Fineline Cube Jul 15, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)—developed...

Company Drug

Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer’s Phase 2 Data

Fineline Cube Jul 15, 2026

Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an...

Company Drug

Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain

Fineline Cube Jul 15, 2026

Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its...

Company Deals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Fineline Cube Jul 15, 2026

Insilico Medicine (HKG: 3696) announced a strategic alliance with Bora Pharmaceuticals (TPE: 6472; OTCMKTS: BORAY)...

Company Drug

Lynk Pharmaceuticals Completes Phase 3 Enrollment for Zemprocitinib in Ankylosing Spondylitis Trial

Fineline Cube Jul 15, 2026

Lynk Pharmaceuticals Co., Ltd. announced that enrollment has been completed for zemprocitinib capsules, a second-generation...

Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026

CR Pharmaceutical Commercial Group and Innovent Biologics (HKG: 1801) have signed a strategic cooperation agreement...

Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026

China’s State Council has issued the “15th Five-Year” National Health Plan, outlining an ambitious roadmap...

Company Drug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Fineline Cube Jul 14, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application...

Policy / Regulatory

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

Fineline Cube Jul 14, 2026

China’s National Healthcare Security Administration (NHSA) announced the completion of its preliminary formal review for...

Company Drug

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

Fineline Cube Jul 14, 2026

B&K Corporation Limited (HKG: 2396) announced the completion of patient enrollment in its Phase II...

Company Drug

Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment

Fineline Cube Jul 14, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection,...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Fineline Cube Jul 14, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that SHR-3079 injection has received...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Fineline Cube Jul 14, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical...

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE:...

Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fineline Cube Jul 14, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector,...

Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Fineline Cube Jul 14, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical...

Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026

Zhaoke Ophthalmology Limited (HKG: 6622) announced the acquisition of global ownership of all intellectual property,...

Company Drug

Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment

Fineline Cube Jul 14, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has submitted a marketing application...

Company Drug

Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease

Fineline Cube Jul 14, 2026

Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China’s National Medical Products Administration (NMPA)...

Insight, China's Pharmaceutical Industry

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination

Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer’s Phase 2 Data

Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Lynk Pharmaceuticals Completes Phase 3 Enrollment for Zemprocitinib in Ankylosing Spondylitis Trial

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment

Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment

Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease

You Missed

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3